School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

LENZ Therapeutics, Inc. LENZ

Healthcare · Biotechnology

$3.64last close 2026-10-09 · market cap $114.53M · delayed data

Trailing returns

1M-25.76%
3M-37.05%
6M-60.76%
1Y-92.12%
5Y-91.81%

Basis: Adjusted daily closes.

What it does

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021.

Open LENZ in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies